![]() |
Sign Up! | Tags | Domains | Searches | Statistics | Options | Advanced Search |
LONDON (MarketWatch) -- LigoCyte Pharmaceuticals Inc. said that it will form a strategic partnership with Biogen Idec to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases. Under the deal, LigoCyte will receive milestone payments on the successful development of drug candidates. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they … Continue Reading »